p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor-Reference-Cited by-同舟云学术

p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor

Published:2020-11-11 Issue: Volume: Page:1-14
ISSN:0739-1102
Container-title:Journal of Biomolecular Structure and Dynamics
language:en
Short-container-title:Journal of Biomolecular Structure and Dynamics

Author:

Ahmad Iqrar¹^ORCID,Shaikh Matin¹,Surana Sanjay¹,Ghosh Arabinda²,Patel Harun¹

Affiliation:

1. Division of Computer Aided Drug Design, Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India

2. Microbiology Division, Department of Botany, Gauhati University, Guwahati, Assam, India

Funder

Indian Council of Medical Research

Publisher

Informa UK Limited

Subject

Molecular Biology,General Medicine,Structural Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/07391102.2020.1844801

Reference65 articles.

1. Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome

2. L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC